Validation, Commissioning & Design Featured Articles

  1. Risk Isn't Inevitable: How The Right CDMO Protects Your Programme 4/13/2026

    Risk in outsourced drug development is often created, not inherent. Learn how CDMO structure, continuity, and communication directly affect programme risk, timelines, and outcomes.

  2. How Asia and Europe Are Reshaping Biologics Manufacturing 4/9/2026

    As biologics manufacturing globalizes, companies must balance cost, capacity, risk, and control when choosing between European and Asian supply bases for clinical and commercial success.

  3. From Principles To Practice: Building Quality Into Generative AI-Assisted Pharma Operations 4/6/2026

    Learn what regulators are already asking about AI, what quality must mean in this new context, and how organizations can begin building the governance infrastructure.

  4. From QM To QMM For AI-Assisted Pharmaceutical Manufacturing Operations 4/1/2026

    The FDA’s focus has shifted from tracking quality metrics to promoting quality management maturity. AI/ML is poised to help with efforts, though it introduces additional complexity around data integrity.

  5. Preventive Maintenance Isn't Enough For GMP Manufacturers 3/31/2026

    Schedule‑based maintenance supports compliance but misses real‑time asset risk. Explore how GMP manufacturers are moving toward condition‑based and predictive strategies to modernize asset management.

  6. Proactive EAM Automation For Compliance And Efficiency 3/31/2026

    Proactive compliance depends on automation. When asset data drives investigations, enforces change control, and reveals hidden failure patterns, compliance becomes an outcome of strong operations.

  7. 5 Ways GMP Manufacturers Can Start Improving Asset Performance Today 3/31/2026

    In GMP operations, poor asset control quickly becomes a compliance risk. Learn how maintenance and calibration gaps lead to deviations and why demonstrable asset performance is essential.

  8. Site Expansion Without Added Compliance Risk 3/31/2026

    Multi-site expansion doesn’t require rebuilding maintenance and calibration programs from scratch. What matters is standardized work, reliable data, and clear oversight that holds up in every facility.

  9. Which Implementation Model Fits Your Reality? 3/31/2026

    CMMS and EAM go-lives in GMP environments hinge on more than timing. Explore how big-bang, phased, compliance-first, and patchwork approaches shift validation effort, audit risk, and operational strain.

  10. SaaS Updates Don't Have To Break Your Validated State 3/31/2026

    SaaS updates don’t have to mean full revalidation. Learn how to apply CSA principles to assess vendor updates, right-size regression testing, and document decisions that hold up under regulatory scrutiny.